Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Shaanxi Panlong Pharmaceutical Group Limited By Share Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shaanxi Panlong Pharmaceutical Group Limited By Share.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.5%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

There Is A Reason Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Price Is Undemanding

Sep 30

Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Shareholders Will Receive A Bigger Dividend Than Last Year

May 31

We Think That There Are Some Issues For Shaanxi Panlong Pharmaceutical Group Limited By Share (SZSE:002864) Beyond Its Promising Earnings

May 02

Earnings Not Telling The Story For Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) After Shares Rise 32%

Mar 06

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Shaanxi Panlong Pharmaceutical Group Limited By Share yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

SZSE:002864 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	936	116	79	156	N/A
3/31/2024	965	120	96	166	N/A
12/31/2023	981	110	42	104	N/A
9/30/2023	997	107	43	93	N/A
6/30/2023	1,043	111	66	113	N/A
3/31/2023	1,001	103	33	87	N/A
1/1/2023	974	101	70	125	N/A
9/30/2022	958	98	77	149	N/A
6/30/2022	917	96	73	151	N/A
3/31/2022	911	96	68	151	N/A
1/1/2022	887	93	35	116	N/A
9/30/2021	842	86	46	136	N/A
6/30/2021	834	89	28	114	N/A
3/31/2021	764	87	-2	76	N/A
12/31/2020	670	79	21	92	N/A
9/30/2020	626	80	5	72	N/A
6/30/2020	565	66	-1	52	N/A
3/31/2020	571	70	38	79	N/A
12/31/2019	611	72	34	68	N/A
9/30/2019	587	76	35	57	N/A
6/30/2019	564	72	41	61	N/A
3/31/2019	516	67	33	53	N/A
12/31/2018	489	65	27	47	N/A
9/30/2018	442	57	22	36	N/A
6/30/2018	424	56	11	22	N/A
3/31/2018	404	46	N/A	30	N/A
12/31/2017	377	44	N/A	28	N/A
9/30/2017	369	49	N/A	41	N/A
6/30/2017	333	44	N/A	62	N/A
3/31/2017	305	40	N/A	52	N/A
12/31/2016	305	40	N/A	62	N/A
12/31/2015	256	43	N/A	41	N/A
12/31/2014	246	40	N/A	49	N/A
12/31/2013	227	33	N/A	25	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if 002864's forecast earnings growth is above the savings rate (2.9%).

Kazançlar ve Piyasa: Insufficient data to determine if 002864's earnings are forecast to grow faster than the CN market

Yüksek Büyüme Kazançları: Insufficient data to determine if 002864's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if 002864's revenue is forecast to grow faster than the CN market.

Yüksek Büyüme Geliri: Insufficient data to determine if 002864's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if 002864's Return on Equity is forecast to be high in 3 years time

Shaanxi Panlong Pharmaceutical Group Limited By Share Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Investor sentiment improves as stock rises 17%

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q3, 2024 Results on Oct 28, 2024

Now 27% overvalued after recent price rise

There Is A Reason Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Price Is Undemanding

New major risk - Financial data availability

Second quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.34 in 2Q 2023)

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report First Half, 2024 Results on Aug 28, 2024

Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Shareholders Will Receive A Bigger Dividend Than Last Year

Dividend increased to CN¥0.22

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Announces Final Dividend on A Shares for the Year 2023, Payable on 03 June 2024

We Think That There Are Some Issues For Shaanxi Panlong Pharmaceutical Group Limited By Share (SZSE:002864) Beyond Its Promising Earnings

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd, Annual General Meeting, May 21, 2024

Now 21% overvalued

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Proposes Final Cash Dividend for the Year 2023

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q1, 2024 Results on Apr 26, 2024

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) announces an Equity Buyback for CNY 20 million worth of its shares.

Earnings Not Telling The Story For Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) After Shares Rise 32%

Investor sentiment deteriorates as stock falls 15%

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.33 (vs CN¥0.39 in 3Q 2022)

Investor sentiment improves as stock rises 18%

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q3, 2023 Results on Oct 30, 2023

Investor sentiment improves as stock rises 16%

Second quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in 2Q 2022)

New minor risk - Dividend sustainability

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report First Half, 2023 Results on Aug 24, 2023

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd. Approves Cash Dividend for 2022

Insufficient new directors

First quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.23 in 1Q 2022)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 15%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd announced that it expects to receive CNY 302 million in funding

Third quarter 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 3Q 2021)

Now 20% undervalued after recent price drop

Investor sentiment improved over the past week

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Approves Management Appointments

Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.29 in 2Q 2021)

Investor sentiment improved over the past week

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Approves 2021 Profit Distribution Plan

Investor sentiment improved over the past week

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Proposes Final Cash Dividend for 2021

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.35 (vs CN¥0.39 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.27 in 2Q 2020)

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd. Announces Cash Dividend for the Year 2020, Payable on May 31, 2021

Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Approves Cash Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.92 (vs CN¥0.83 in FY 2019)

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Fiscal Year 2020 Results on Apr 13, 2021

New 90-day low: CN¥22.24

New 90-day low: CN¥23.85

New 90-day low: CN¥25.17

Third quarter earnings released

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥25.52

New 90-day low - CN¥27.25

Earnings released

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd to Report First Half, 2020 Results on Aug 25, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin